Boston Scientific Unrecognized tax benefits decreased by 0.4% to $529.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 7.3%, from $493.00M to $529.00M. Over 4 years (FY 2020 to FY 2024), Unrecognized tax benefits shows an upward trend with a 18.0% CAGR. This is a positive signal — lower values indicate better performance for this metric.
A decrease suggests the resolution of tax audits or the expiration of statutes of limitations, while an increase suggests new tax positions with higher uncertainty.
This represents the aggregate amount of tax benefits that have not been recognized in the financial statements because t...
Peers generally maintain low levels of unrecognized tax benefits to minimize audit risk and financial statement volatility.
other_unrecognized_tax_benefits| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $280.00M | $277.00M | $255.00M | $262.00M | $411.00M | $419.00M | $492.00M | $501.00M | $471.00M | $475.00M | $467.00M | $465.00M | $478.00M | $493.00M | $506.00M | $514.00M | $531.00M | $529.00M |
| QoQ Change | — | -1.1% | -7.9% | +2.7% | +56.9% | +1.9% | +17.4% | +1.8% | -6.0% | +0.8% | -1.7% | -0.4% | +2.8% | +3.1% | +2.6% | +1.6% | +3.3% | -0.4% |
| YoY Change | — | — | — | — | +46.8% | +51.3% | +92.9% | +91.2% | +14.6% | +13.4% | -5.1% | -7.2% | +1.5% | +3.8% | +8.4% | +10.5% | +11.1% | +7.3% |